- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| Fr | Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans | 131 | GlobeNewswire (Europe) | HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026... ► Artikel lesen | |
| 11.03. | IMPACT BIOMEDICAL INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 9 | SEC Filings | ||
| 07.11.25 | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Aktionäre von Impact Biomedical bestätigen Direktoren und Wirtschaftsprüfer auf Jahreshauptversammlung | 14 | Investing.com Deutsch | ||
| 18.08.25 | Impact Biomedical Inc (IBO) Announces 3F US Patent Issue | 315 | GlobeNewswire (Europe) | HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition... ► Artikel lesen | |
| 24.06.25 | DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger | 387 | GlobeNewswire (Europe) | NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management... ► Artikel lesen | |
| 23.06.25 | IMPACT BIOMEDICAL INC; Dr Ashleys Limited: Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger | 475 | GlobeNewswire (Europe) | A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,435 | +3,34 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,810 | 0,00 % | Stifel initiates Summit Therapeutics stock with buy rating | ||
| IMMUNOVANT | 24,730 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| EVOTEC | 4,676 | +4,61 % | EQS-News: Evotec SE: Evotec ernennt Dr. Ashiq H. Khan zum Chief Commercial Officer | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Dr. Ashiq H. Khan zum Chief Commercial Officer
01.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIONTECH | 79,05 | +2,20 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| ARCELLX | 114,79 | -0,01 % | Gilead extends Arcellx tender offer deadline to April 24 | ||
| VERA THERAPEUTICS | 40,360 | +0,75 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,515 | +7,60 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | ||
| ADMA BIOLOGICS | 9,820 | +5,93 % | Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026? | ||
| COGENT BIOSCIENCES | 36,950 | +3,76 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| ERASCA | 16,940 | -0,70 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 102,00 | -1,60 % | Clear Street raises Protagonist Therapeutics price target on drug potential | ||
| BEAM THERAPEUTICS | 25,450 | +3,88 % | Beam Therapeutics publishes sickle cell therapy trial data | ||
| PRAXIS PRECISION MEDICINES | 319,62 | +4,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 42,890 | -0,69 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details |
IMPACT BIOMEDICAL INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.